Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
10.6M
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
3.88M
-
Shares change
-
+1.96M
-
Total reported value, excl. options
-
$4.58M
-
Value change
-
+$2.33M
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$1.18
Significant Holders of Aridis Pharmaceuticals, Inc. - Common Stock (ARDS) as of Q4 2022
20 filings reported holding ARDS - Aridis Pharmaceuticals, Inc. - Common Stock as of Q4 2022.
Aridis Pharmaceuticals, Inc. - Common Stock (ARDS) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.88M shares
of 10.6M outstanding shares and own 36.6% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (2.07M shares), COMMONWEALTH EQUITY SERVICES, LLC (575K shares), VANGUARD GROUP INC (524K shares), Roumell Asset Management, LLC (447K shares), GEODE CAPITAL MANAGEMENT, LLC (143K shares), STATE STREET CORP (43.2K shares), NORTHERN TRUST CORP (28.1K shares), BlackRock Inc. (17.3K shares), Wealth Architects, LLC (14.1K shares), and Tower Research Capital LLC (TRC) (9.63K shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.